7 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Pap tests are normal ... Preventing First ... #Treatment #management ... #HIVAIDS #pharmacology
Triptan Selection - Migraine Management
Choosing triptans:
 • Reponse to given triptan do not predict to others
Selection - Migraine Management ... • Fast-acting oral ... response: • Consider preventive ... #treatment #neurology ... #pharmacology #
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
for effective treatment ... mucosal #IDSA #Prevention ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
response preceding infection ... CSF PROTEIN - NORMAL ... Treatment: • Plasmapheresis ... Syndrome #diagnosis #management ... #treatment #neurology
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
Recommendations for Preventing ... • Aggressive oral ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
recommended for KS treatment ... specialist) + ART • Oral ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
regress, change to oral ... • Continue treatment ... HerpesSimplex #HSV #IDSA #Prevention ... #Treatment #management ... #HIVAIDS #pharmacology